There is no accepted staging system for pheochromocytoma.

Localized benign

Data suggest that for patients with resectable, benign pheochromocytoma, the overall survival is equal to that of the age-matched normal population.[1,2]

Regional

No information is available at this time.

Metastatic

Data from several series suggest that the 5-year survival rate for patients with metastatic, malignant pheochromocytoma is approximately 40%.[1-3] In three retrospective studies of patients with either metastatic or recurrent pheochromocytoma, the 5-year survival ranged from 32% to 60%.[4]

References

1. Douglass EC, Shapiro DN, Valentine M, et al.: Alveolar rhabdomyosarcoma with the t(2;13): cytogenetic findings and clinicopathologic correlations. Med Pediatr Oncol 21 (2): 83-7, 1993.  [PUBMED Abstract]
   
   
2. Remine WH, Chong GC, Van Heerden JA, et al.: Current management of pheochromocytoma. Ann Surg 179 (5): 740-8, 1974.  [PUBMED Abstract]
   
   
3. van Heerden JA, Sheps SG, Hamberger B, et al.: Pheochromocytoma: current status and changing trends. Surgery 91 (4): 367-73, 1982.  [PUBMED Abstract]
   
   
4. Kvols LK, Perry RR, Vinik AI, et al.: Neoplasms of the neuroendocrine system and neoplasms of the gastroenteropancreatic endocrine system. In: Holland JC, Frei E, eds.: Cancer Medicine e.5. 5th ed. Hamilton, Ontario: B.C. Decker Inc, 2000, pp 1121-1172.